Eli Lilly and Company will invest $6.5 billion to establish a one million-square-foot active pharmaceutical ingredient (API) manufacturing facility in Harris County, marking the largest life sciences investment in Texas history. The project is expected to create more than 600 new jobs and strengthen the domestic drug supply chain.
The facility, located at Generation Park, will focus on next-generation synthetic medicines. The investment was secured with the support of a $5.5 million Texas Enterprise Fund grant and backing from the state’s Jobs, Energy, Technology, and Innovation (JETI) program.
“This significant U.S. investment and onshoring of our API production capabilities will ensure faster, more secure access to orforglipron and to other life-changing medicines of the future,” said David A. Ricks, CEO of Eli Lilly. The company has announced eight new U.S. manufacturing sites since 2020 as part of its effort to expand capacity and secure supply chains.
Harris County Commissioner Rodney Ellis emphasized the local impact. “Lilly’s decision to invest more than $6.5 billion in Harris County is a powerful testament to the strength of our community and its ability to support lifesaving work in the life sciences and create living wage jobs and equitable economic opportunities for working families,” Ellis said.
Governor Greg Abbott praised the project as a transformative step for the Greater Houston area and Texas’s life sciences sector. Officials highlighted the facility’s potential to accelerate innovation, support workforce development, and position Texas as a key player in pharmaceutical manufacturing.
